The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 20; p. 3272
• Main Authors: Svensson, Camilla Kara, Cold, Frederik, Ribberholt, Iben, Zangenberg, Mike, Mirsepasi-Lauridsen, Hengameh Chloé, Petersen, Andreas Munk, Helms, Morten
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.10.2022; MDPI
• Subjects: Antibiotics; CDI; Clostridioides difficile; Clostridioides difficile infection; Clostridium Infections - therapy; Cohort analysis; Diarrhea; Drug dosages; Endoscopy; faecal microbiota transplantation; Fecal Microbiota Transplantation - adverse effects; FMT; Hospitals; Humans; Infectious diseases; Laboratories; Microbiota; Patients; RBT; rectal bacteriotherapy; Rectum; Recurrent infection; Regression analysis; Retrospective Studies; Transplantation; Transplants & implants; Treatment Outcome; Variance analysis; faecal microbiota transplantation; CDI; Clostridioides difficile infection; rectal bacteriotherapy; FMT; RBT
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11203272

The most effective treatment for recurrent Clostridioides difficile infection (CDI) is faecal microbiota transplantation (FMT); however, the optimal route of administration is thus far unknown. This retrospective cohort study of 343 patients sought to evaluate the efficacy of treatment with FMT capsules, FMT enema, and rectal bacteriotherapy (RBT) during a five-year period. The primary endpoint was clinical resolution from CDI after eight weeks, and secondary endpoints were time to recurrence and death during the follow-up period. The proportion of patients with clinical resolution was 79.9% in the FMT capsule group, 53.3% in the FMT enema group, and 61.8% in the RBT group, corresponding to an adjusted odds ratio of 3.79 (CI: 1.82 to 8.26) in the FMT capsule group compared with FMT enema, and 2.92 (CI: 1.49 to 6.03) compared with RBT. The hazards ratio for recurrence within the first 12 months of follow-up was 0.24 (CI: 0.06 to 0.89) in the FMT capsule group compared with FMT enema, and 0.26 (CI: 0.08 to 0.91) compared with RBT. There was no difference in mortality. In conclusion, FMT capsules were more effective than both FMT enema and RBT as treatment of recurrent CDI and reduced the risk of further recurrences.